Overview
ZBIO market data
Price History
ZBIO price chart · 1M
- O
- 33.11
- H
- 33.47
- L
- 32.45
- C
- 32.65
- Vol
- 68,501.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $33.11
- Previous Close
- $33.05
- Day High
- $33.47
- Day Low
- $32.45
- 52 Week High
- $34.02
- 52 Week Low
- $16.44
- 7 Day Return
- +3.37%
- 30 Day Return
- +1.26%
- 90 Day Return
- +77.51%
- 1 Year Return
- +86.12%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,777.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.50 – $44.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2B · P/B 8.05.
Company News
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32Benzinga · Aug 14, 2026, 6:07 PM
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price TargetBenzinga · Aug 14, 2026, 1:37 PM
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price TargetBenzinga · Aug 14, 2026, 1:07 PM
Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M EstimateBenzinga · Aug 13, 2026, 11:24 AM
8-K filing — Zenas BioPharma, Inc. (ZBIO)SEC EDGAR · Aug 13, 2026, 11:05 AM
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga · Jun 12, 2026, 12:05 PM